AIMS: To examine the prevalence of psychotic symptoms among regular methamphetamine users. DESIGN: Cross-sectional survey. SETTING: Participants were recruited from Sydney, Australia, through advertisements in free-press magazines, flyers and through word-of-mouth. PARTICIPANTS: Methamphetamine users (n = 309) who were aged 16 years or over and took the drug at least monthly during the past year. MEASUREMENTS: A structured face-to-face interview was used to assess drug use, demographics and symptoms of psychosis in the past year. Measures of psychosis included: (a) a psychosis screening instrument derived from the Composite International Diagnostic Interview; and (b) the Brief Psychiatric Rating Scale subscales of suspiciousness, unusual thought content, and hallucinations. Dependence on methamphetamine was measured using the Severity of Dependence Scale. FINDINGS: Thirteen per cent of participants screened positive for psychosis, and 23% had experienced a clinically significant symptom of suspiciousness, unusual thought content or hallucinations in the past year. Dependent methamphetamine users were three times more likely to have experienced psychotic symptoms than their non-dependent counterparts, even after adjusting for history of schizophrenia and other psychotic disorders. CONCLUSION: The prevalence of psychosis among the current sample of methamphetamine users was 11 times higher than among the general population in Australia. Dependent methamphetamine users are a particularly high-risk group for psychosis.
AIMS: To examine the prevalence of psychotic symptoms among regular methamphetamine users. DESIGN: Cross-sectional survey. SETTING:Participants were recruited from Sydney, Australia, through advertisements in free-press magazines, flyers and through word-of-mouth. PARTICIPANTS: Methamphetamine users (n = 309) who were aged 16 years or over and took the drug at least monthly during the past year. MEASUREMENTS: A structured face-to-face interview was used to assess drug use, demographics and symptoms of psychosis in the past year. Measures of psychosis included: (a) a psychosis screening instrument derived from the Composite International Diagnostic Interview; and (b) the Brief Psychiatric Rating Scale subscales of suspiciousness, unusual thought content, and hallucinations. Dependence on methamphetamine was measured using the Severity of Dependence Scale. FINDINGS: Thirteen per cent of participants screened positive for psychosis, and 23% had experienced a clinically significant symptom of suspiciousness, unusual thought content or hallucinations in the past year. Dependent methamphetamine users were three times more likely to have experienced psychotic symptoms than their non-dependent counterparts, even after adjusting for history of schizophrenia and other psychotic disorders. CONCLUSION: The prevalence of psychosis among the current sample of methamphetamine users was 11 times higher than among the general population in Australia. Dependent methamphetamine users are a particularly high-risk group for psychosis.
Authors: Brenda M Booth; Geoffrey Curran; Xiaotong Han; Patricia Wright; Sarah Frith; Carl Leukefeld; Russel Falck; Robert G Carlson Journal: J Stud Alcohol Drugs Date: 2010-03 Impact factor: 2.582
Authors: Erin E Morgan; Steven P Woods; Amelia J Poquette; Ofilio Vigil; Robert K Heaton; Igor Grant Journal: Aust N Z J Psychiatry Date: 2012-02 Impact factor: 5.744
Authors: J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant Journal: Neuropsychol Rev Date: 2007-09 Impact factor: 7.444
Authors: Peter D Alexander; Kristina M Gicas; Taylor S Willi; Clara N Kim; Veronika Boyeva; Ric M Procyshyn; Geoff N Smith; Allen E Thornton; William J Panenka; Andrea A Jones; Fidel Vila-Rodriguez; Donna J Lang; G William MacEwan; William G Honer; Alasdair M Barr Journal: Psychopharmacology (Berl) Date: 2017-02-11 Impact factor: 4.530
Authors: Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison Journal: Addiction Date: 2014-03-17 Impact factor: 6.526
Authors: Susan G Sherman; Catherine Sutcliffe; Bangorn Srirojn; Carl A Latkin; Apinun Aramratanna; David D Celentano Journal: Soc Sci Med Date: 2008-11-03 Impact factor: 4.634